ÁC

Á. Callejo Mellén

AstraZeneca (Spain)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Carlos Aguado

Hospital Clínico San Carlos

RÁ

R. Álvarez Cabellos

Hospital Virgen de la Salud

Jan Lötvall

University of Gothenburg

J.M. Oramas Rodriguez

Hospital Universitario de Canarias

Mona Palmqvist

University of Gothenburg

V. Gutiérrez Calderón

Hospital Regional Universitario de Málaga

Edurne Arriola

Hospital Del Mar

J.L. Martí Ciriquián

Hospital General Universitario de Alicante Doctor Balmis

M.R. García Campelo

Complexo Hospitalario Universitario A Coruña

A. Sánchez-Hernández

Center for Research and Advanced Studies of the National Polytechnic Institute

Cooperative Institutions

Sahlgrenska University Hospital

University of Gothenburg

Parc de Salut

Region Västra Götaland

Centro de Investigación Biomédica en Red de Cáncer

Lund University

Hospital Del Mar

Instituto de Salud Carlos III

Complexo Hospitalario Universitario A Coruña

Karolinska Institutet

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

165P SCLC subtypes are associated with distinct dinicopathological features and outcomes: A biomarker analysis from the CANTABRICO study

Journal of Thoracic Oncology (2023)

P. Rocha I. Sanchez L. Masfarre Pinto M. Giner N. Navarro Gorro

Univariate analysis

Durvalumab

10.1016/s1556-0864(23)00419-7

Cite

Citations (1)

Rhizarthrosis in banknote processing workers: a retrospective cohort study

Occupational Medicine (2017)

G Verrijdt Anaïs De Landtsheer Á. Callejo Mellén Lode Godderis

Rhizarthrosis, or osteoarthritis of the base of the thumb, is a common condition affecting 10-30% of the population over the age of 60. Whether it is an occupational disease has been the subject of debate as epidemiological studies on the correlation between physical stress and the presence of rhizarthrosis have shown conflicting results.To study the correlation between the prevalence of rhizarthrosis and the time spent by employees manually processing banknotes at the National Bank of Belgium (NBB).We followed NBB employees currently or previously holding job titles involving the manual or automated processing of banknotes. Each participant's job history was carefully reconstructed and the number of months holding certain job titles determined. Each participant was clinically and radiologically examined for the presence of rhizarthrosis in both hands. Its presence was scored by a combination of clinical and radiological criteria.There were 195 participants. The prevalence of rhizarthrosis was 27% in women (mean age: 52.3 ± 4.4 years) and 17% in men (mean age: 53.2). The odds ratio (OR) for rhizarthrosis after 10 years' full-time overall exposure was significantly higher [OR 10 years: 1.53 (1.03-2.28)]. However, one particular job, 'manual counting', described by participants as highly straining and severely taxing on the thumbs, did not show a significantly higher prevalence of rhizarthrosis.Our study confirmed the correlation between the presence of rhizarthrosis and age, gender and general manual labour, in particular banknote processing, but found no link with one specific job-manual counting.

Banknote

10.1093/occmed/kqx144

Cite

Citations (3)

Equivalent therapeutic ratio of salbutamol given by Turbuhaler®and Diskus™

Respiratory Medicine (2000)

Peter Arvidsson Á. Callejo Mellén Mona Palmqvist Jan Lötvall

10.1053/rmed.1999.0778

Cite

Citations (13)

1667TiP Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study

Annals of Oncology (2021)

Luís Paz-Ares Edurne Arriola M.R. García Campelo María Pilar Diz Taín M.C. Marti Blanco

Durvalumab

10.1016/j.annonc.2021.08.251

Cite

Citations (2)

The Impact of Smoking on Inhaled Insulin

Diabetes Care (2003)

Anders Himmelmänn Johan Jendle Á. Callejo Mellén Astrid H. Petersen Ulf Dahl

This study, one of the first to address issues of pulmonary insulin delivery in smokers, compared pharmacokinetics of inhaled insulin delivered via the AERx insulin Diabetes Management System (iDMS) in nondiabetic cigarette smokers and nonsmokers.In this randomized two-period crossover efficacy and safety trial in 27 nondiabetic smokers and 16 nonsmokers (18 men/25 women, mean age 28 years, mean BMI 23.0 kg/m(2)), subjects received single doses of inhaled insulin (33.8 IU) following overnight fasting on consecutive dosing days. On one dosing day, smokers smoked three cigarettes immediately before insulin administration ("acute smoking"); on the other dosing day, smokers had not smoked since midnight ("nonacute smoking"). After inhalation, 6-h serum insulin and serum glucose profiles were determined.Pharmacokinetic results for evaluable subjects were derived from serum insulin profiles. The amount of insulin absorbed during the first 6 h after dosing (area under the exogenous serum insulin curve from 0 to 6 h [AUC((0-6 h))]) was significantly greater in smokers (63.2 vs. 40.0 mU l(-1) x h(-1), P = 0.0017); peak concentration was both higher and earlier in the smokers (maximal serum concentration of insulin [C(max)] 42.0 vs. 13.9 mU/l, P < 0.0001; time to maximal serum concentration of insulin [t(max)] 31.5 vs. 53.9 min, P = 0.0003). The estimated intrasubject variability of AUC((0-6 h)) was 13.7 and 16.5% for nonsmokers and smokers, respectively. No safety issues arose.Absorption of inhaled insulin via the AERx iDMS was significantly greater in smokers, with a higher AUC((0-6 h)) and C(max) and a shorter t(max). Intrasubject variability of AUC((0-6 h)) was low and similar in nonsmokers and smokers. These data prompt more extensive investigation of inhaled insulin in diabetic smokers.

Crossover study

Regular insulin

10.2337/diacare.26.3.677

Cite

Citations (128)

1532P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results

Annals of Oncology (2022)

D. Isla E. Arriola M.R. García Campelo P. Diz Tain C. Marti Blanco

Durvalumab

10.1016/j.annonc.2022.07.1627

Cite

Citations (3)

Physical activity on prescription in accordance with the Swedish model increases physical activity: a systematic review

British Journal of Sports Medicine (2018)

Aron Onerup Daniel Arvidsson Åse Blomqvist Eva-Lotte Daxberg Lennart Jivegård

Objectives This study investigates the effects of the core elements of the Swedish model for physical activity on prescription (PAP) by evaluating studies that compared adults who received PAP with adults who did not receive PAP. All participants were adults identified by a healthcare professional as in need of increased physical activity. Primary outcome was level of physical activity. Design Systematic review. Eligibility criteria (1) Published 1999. (2) Systematic review, randomised controlled trial (RCT), non-RCT or case series (for adverse events). (3) ≥12 weeks’ follow-up. (4) Performed in the Nordic countries. (5) Presented in English, Swedish, Norwegian or Danish. Data sources Systematic searches in PubMed, Embase, the Cochrane Library, AMED, CINAHL and SweMed+ in September 2017. Included articles were evaluated using checklists to determine risk of bias. Results Nine relevant articles were included: seven RCTs, one cohort study and one case series. Primary outcome was reported in seven articles from six studies (five RCTs, one cohort study, 642 participants). Positive results were reported from three of the five RCTs and from the cohort study. No study reported any negative results. Swedish PAP probably results in an increased level of physical activity (GRADE⊕⊕⊕Ο). Conclusions Although the number of the reviewed articles was relatively modest, this systematic review shows that PAP in accordance with the Swedish model probably increases the level of physical activity. As a model for exercise prescription, Swedish PAP may be considered as part of regular healthcare to increase physical activity in patients.

CINAHL

Norwegian

10.1136/bjsports-2018-099598

Cite

Citations (105)

Use of and attitudes towards the prescribing guidelines booklet in primary health care doctors

BMC Clinical Pharmacology (2008)

Magnus Axelsson Malin Spetz Á. Callejo Mellén Susanna M. Wallerstedt

In the region of Västra Götaland in Sweden, prescribing guidelines, drawn up by 24 expert groups and determined by the regional board for drugs, are since 2006 available in the form of an annually published booklet. This study investigates, for the first time, the use of and attitudes towards this publication.A questionnaire was administered to doctors working in primary health care in the region of Västra Götaland in Sweden. Questions included characteristics of the responding doctor and use of the prescribing guidelines booklet, as well as attitude questions constructed as statements to which the responder should grade his level of agreement from 1 (total disagreement) to 6 (total agreement).Totally 603 filled-in questionnaires were returned (estimated response rate 60%). The majority of the doctors (n = 571, 97%) responded that they use the prescribing guidelines booklet, and when prescribing a drug for a new diagnosis, a drug from the booklet is chosen in most cases [median (25th - 75th percentile) 80 (75-90)]. However, at renewal of a drug prescription, active change to a drug from the prescribing guidelines booklet occurs less often [median (25th - 75th percentile) 50 (20-70)]. The booklet also includes short therapy advice sections, which 231 doctors (42%) use every day and 191 (34%) use every week. The attitudes towards the prescribing guidelines booklet were generally positive. Doctors in privately run primary health care units and doctors running their own business were generally more negative and judged themselves to be less adherent to the prescribing guidelines booklet compared with doctors in publicly run primary health care units.The prescribing guidelines booklet is frequently used and is generally appreciated, though differences exist between subgroups of users.

10.1186/1472-6904-8-8

Cite

Citations (11)

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

American Journal of Respiratory and Critical Care Medicine (1999)

Mona Palmqvist T Ibsen Á. Callejo Mellén Jan Lötvall

Studies performed on airway smooth muscle in vitro have indicated that salmeterol is a partial agonist on the β2-receptor in comparison to formoterol. In the present study we evaluated whether these pharmacological differences between salmeterol and formoterol also are applicable to asthmatic patients. The protective effects by increasing cumulative doses of formoterol (12, 60, 120 μ g) and salmeterol (50, 250, 500 μ g) on methacholine-induced bronchoconstriction were evaluated in a double-blind, crossover, placebo-controlled design. Patients were regularly treated with salbutamol 200 μ g twice daily during the study period, to avoid variability in β2-adrenoceptor tolerance. S-potassium, heart rate corrected Q-T interval (Q-Tc), and tremor score were followed as measures of systemic effects. Formoterol dose-dependently protected against methacholine responsiveness (4.6 doubling doses after 120 μ g). Salmeterol, however, showed a flatter dose–response curve, and a significantly weaker maximal protective effect (2.8 doubling doses after 250 μ g). Formoterol caused a significantly higher tremor score and a larger drop in S-potassium than salmeterol at the highest doses. These data show that salmeterol is a partial agonist on the β2-receptor in relation to formoterol in human airways in vivo. Further studies are required to document the clinical consequences of this finding, for example in severe asthmatic patients.

Salmeterol

Methacholine

Crossover study

Formoterol Fumarate

10.1164/ajrccm.160.1.9901063

Cite

Citations (174)

ENHANCED BLOOD PRESSURE LOWERING EFFECT IN HYPERTENSIVE PATIENTS ON COMBINED SILDENAFIL AND LERCANIDIPINE TREATMENT

Journal of Hypertension (2000)

Thomas Hedner Bart Everts H. Kraizci Á. Callejo Mellén Caroline Olsson

s: Wednesday, May 31, 2000: POSTER SESSIONS: POSTER SESSION 17: Therapeutic and Clinical Pharmacology (TH)

Lercanidipine

10.1097/00004872-200006001-00564

Cite

Citations (2)